Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.K.'s NICE Rejects Lucentis For Macular Edema; Avastin Remains Poised For Appraisal

This article was originally published in The Pink Sheet Daily

Executive Summary

NICE's preliminary rejection of Lucentis for macular edema paves the way for cheaper Avastin to swallow up most of the U.K. market.

You may also be interested in...



NICE OK For Bayer’s Eylea In AMD May Spell U.K. Trouble For Lucentis

NICE has given the thumbs-up to Bayer’s Eylea in wet AMD, but its impressive cost-effectiveness could spell trouble for Novartis’ Lucentis in the long run.

NICE Nod To Lucentis For ME Raises Unlicensed Comparator Issue

The U.K.’s cost watchdog NICE has waved through Novartis’ Lucentis for macular edema after the Swiss manufacturer offered a discount.

Novartis To Appeal NICE's Rejection Of Lucentis For Diabetic Macular Edema

NICE, the U.K.'s cost regulator, fails to recommend Novartis' Lucentis for diabetic macular edema in final draft guidance; Swiss company to appeal.

Related Content

Topics

UsernamePublicRestriction

Register

OM009724

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel